Pharmaceutical Reverse Payments and Lower Drug Costs: An Interesting Dilemma
10:43 AM | July 26, 2010 | Girish Malhotra
The U.S. Federal Trade Commission and the lawmakers have scorned the concept of the ‘reverse payment’ - also called “pay-for delay” - in the pharmaceutical business. The U.S. House of Representative...
This information is only available to subscribers
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.